New strategies for mismatched unrelated donor (MMUD) hematopoietic cell transplant (HCT).
Hematology Am Soc Hematol Educ Program
; 2022(1): 74-82, 2022 12 09.
Article
in En
| MEDLINE
| ID: mdl-36485163
ABSTRACT
With increasing numbers of patients with hematologic malignancies requiring allogeneic hematopoietic cell transplant (HCT), including minority racial and ethnic groups, the limited availability of matched related donors and matched unrelated donors remains a significant obstacle. Hence, the use of alternative donors such as haploidentical and mismatched unrelated donors (MMUDs) is on the rise. Herein, we present case studies to outline a rational and stepwise approach with a focus on the use of MMUD for HCT in patients with hematologic malignancies. We also review novel approaches used to reduce the incidence of severe graft-versus-host disease and improve HCT outcomes in patients undergoing MMUD HCT.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Hematopoietic Stem Cell Transplantation
/
Hematologic Neoplasms
/
Graft vs Host Disease
Type of study:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limits:
Humans
Language:
En
Journal:
Hematology Am Soc Hematol Educ Program
Journal subject:
HEMATOLOGIA
Year:
2022
Document type:
Article
Affiliation country:
Canada